Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 54 No. 3
PSYCHOPHARMACOLOGY BULLETIN

VOL 54 No. 3

Articles in This Issue

EDUCATIONAL REVIEW - 2024

The Black Book of Psychotropic Dosing and Monitoring

Charles DeBattista, Alan F Schatzberg
Introduction Since the last edition of the Black Book, several innovative agents have been approved or are poised to be approved in the coming year. These include novel antidepressants, the first muscarine agonist for the...
Pages 8-59 Read Article
ORIGINAL RESEARCH

Association Between Symptom Severity and Medication Adherence in Adults with Bipolar Disorder Reporting Adherence Challenges

Martha Sajatovic, Farren Briggs, Clara Adeniyi, Jacob Koopman, Jessica Black, Celeste Weise, Nicole Fiorelli, Joy Yala, Mohammad Lesanpezeshki, Douglas Einstadter, Jennifer B Levin
Background Given the importance of medication adherence among individuals with bipolar disorder (BD), this analysis from an ongoing randomized controlled trial (RCT) examined the relationship between BD symptoms, functioning and adherence in 69 poorly adherent...
Pages 60-72 Read Article
GENERAL PSYCHIATRY

Intravenous Lidocaine for the Management of Chronic Pain: A Narrative Review of Randomized Clinical Trials

Henry Onyeaka, Janet Adeola, Rebecca Xu, Adlai Liburne Pappy, Sarah Adeola, Marchelle Smucker, Albert Chang, Anthony Fraga, Wisdom Ufondu, Moyasar Osman, Jamal Hasoon, Vwaire J Orhurhu
Background Chronic pain remains a serious health problem with significant impact on morbidity and well-being. Available treatments have only resulted in relatively modest efficacy. Thus, novel therapeutic treatments with different mechanisms have recently generated empirical...
Pages 73-96 Read Article
LETTER TO THE EDITOR

Neuropsychiatry of Histaminergic Circuits: Potential Role of Novel H3 Receptor Selective Antagonist/ Inverse Agonist Pitolisant in Prader-Willi Syndrome

Beatriz Freitas, Tomas P Teodoro
Histamine and its receptors have been implicated in several neuropsychiatric conditions including Gilles de la Tourette syndrome, schizophrenia, attention deficit hyperactivity disorder, narcolepsy, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, epilepsy, and substance use disorders.1–3 Histaminergic...
Pages 103-107 Read Article